Acutaas Chemicals Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Pricing pressure forced a top-line compromise: Revenue grew 17% YoY to ₹172 crores, but Chinese oversupply drove price erosion that management absorbed to defend market share, pulling the FY24 growth target down to ~20%.
• Margins collapsed on a cluster of one-offs: Gross margin fell to 41% and EBITDA margin to 14.4%, hit by high-cost inventory, a product-mix shift toward lower-margin domestic and specialty business, a machinery breakdown, and the delay of a high-margin pharma launch.
• PAT turned negative on a non-cash impairment: A ₹17 crore net loss came entirely from fully impairing the Ami Oncotheranostics drug-discovery JV; excluding it, PAT would have been ₹14.7 crores.
• The Fermion ramp and Ankleshwar facility are the H2 story: Validation batches begin in December, first shipments in Q4 FY24, and commercial supply scales in H2 FY25, with a third intermediate now added to the contract.
• What to watch next quarter: Whether gross margins actually snap back to 48% as guided, the pace of pricing-renegotiation recovery, and any concrete customer wins for the remaining 66% of Ankleshwar capacity.

The Pricing Shock: Chinese Oversupply and Market-Share Defense

• Oversupply hit finished-goods prices: Chinese production continues to outpace demand across the chemical value chain, pushing down raw material costs but also finished-goods pricing, with competitors accessing cheaper Chinese inputs and undercutting on domestic spot business.
• Long inventory cycle amplified the pain: Ami Organics held 1–2 quarters of higher-cost raw material inventory and could not match competitors' lower quotes immediately; the company has since informed customers and is reducing domestic inventory.
• Volume held, price gave way: Management explicitly chose to compromise on top-line price rather than lose volume, preserving market leadership; volume growth is expected at 20–25% for the year even as revenue growth guidance dropped from 25% to ~20%.
• Renegotiations have clawed back much of the damage: The 6–7% EBITDA margin hit from price erosion has been largely recovered through renegotiations over the past 1–1.5 months, and management states pricing pressure will not impact going forward.
• Competitive moat holds in the top 10 products: In its largest revenue-contributing molecules, Ami dominates Chinese manufacturers on manufacturing cost, technology, approvals, and DMF positioning; the top 5 products are consistently growing.

Nareshkumar R. Patel: "To avoid losing the market share, we compromise on the top line, and this is how we maintain the market share. The volume is already there. Only to remain as the market leader, we have to compromise on the top line."

Margin Walk: What Broke and What Mends

• Gross margin fell to 41% from three forces: High-cost inventory meeting lower finished-goods prices (a one-quarter effect), a product-mix shift toward the domestic market (structurally 2–3% lower margin), and strong growth in the lower-margin specialty chemicals business.
• EBITDA margin dropped to 14.4% from 19.1%: Beyond the gross-margin squeeze, employee costs rose on annual increments, ESOP charges, and hiring for the Ankleshwar factory, while a one-off machinery breakdown in the waste-management area forced costly outside treatment.
• A high-margin product delay deepened the hit: A key anticoagulant product for a first-to-file generic customer was delayed when the originator won a litigation in one territory; sales will be muted through Q4 FY24, resuming fully only in FY25.
• Recovery is guided to be swift: Management expects gross margins to return to 48% from Q3 onwards as raw material prices have stabilized and the high-cost inventory works through the system.

Nareshkumar R. Patel: "High-cost inventory is not related to quote like that, but it is related to the spot business as well as short term only. So, it will very drastically go back to 48% in the next couple of quarters."

Fermion Partnership and Ankleshwar: The Growth Engine Taking Shape

• Fermion contract expanded to three advanced intermediates: One more intermediate was added during the quarter; orders for previously signed intermediates have been received, and shipping from the Ankleshwar facility begins in Q4 FY24.
• Validation timeline is locked: Validation batches for the first intermediate have started; validations for the other two begin in the second half of December at Ankleshwar, with commercial supply scaling in H2 FY25 toward full utilization.
• Ankleshwar capacity is 33% booked, 66% open: The facility acquired from Gujarat Organics is pharma-only across three blocks; one block is fully dedicated to Fermion, while the remaining two-thirds are free for own use until FY27, with pipeline discussions underway for exclusive manufacturing with other customers.
• Management declined to quantify the Fermion contract value increase when asked for the percentage uplift from adding the third intermediate, citing confidentiality between two listed companies.

Specialty Chemicals and New Products: Volume Growth, Margin Dilution

• Specialty chemicals surged 72% YoY: Volume growth was strong but pricing pressure persisted, and the segment's lower margin profile contributed to the overall gross-margin decline.
• UV absorber launch adds a new vertical: A product for automobile metallic painting, developed with Swiss scientists, has finished validation batches and begun small-quantity distribution; revenue is expected from Q3 FY24 onwards, with a long-term target of 600–1,000 metric tons once fully approved.
• Electrolyte additive business is at the starting line: Production begins this quarter with raw material orders placed; a first trial order is confirmed, and supply starts from Q4, with management hoping to convert a couple of prospects in the current quarter.
• Specialty segment ambition is aggressive: Management targets at least 2.5x growth in the specialty segment over the next couple of years, with big-buyer negotiations underway and a possible announcement in the coming weeks.

Acquisitions and Impairments: Baba Fine Chemicals Onboarded, JV Written Off

• Baba Fine Chemicals acquisition closed: The controlling partnership was acquired for ₹68 crores with goodwill of approximately ₹54–56 crores; the entity will be succeeded by a newly incorporated entity, Baba Advance Materials Limited.
• FY24 is a consolidation year for Baba: H1 was largely consumed by integration work including system transfers, digitalization, and customer approvals for management changes; FY25 is expected to ramp up exponentially, with a long-term target of ₹200–250 crores in 4–5 years.
• Ami Oncotheranostics JV was fully impaired: The drug-discovery investment was written off because the work was moving too slowly and management concluded it was not Ami Organics' core competency; the impairment drove the reported net loss.

Nareshkumar R. Patel: "The drug discovery is not a cup of tea for Ami Organics, and once we have seen that, it's moving very sluggishly. So, we decided to not to have more carryover of this as just a side investment and so we decided to focus more on our current chemistry..."

Balance Sheet and Operational Items

• Inventory days jumped from ~100 to ~145: The buildup was strategic, driven by stockpiling for the upcoming Fermion contract validations, which have tight qualification windows.
• Raw material inventory rose from ₹78 crores to ₹100 crores QoQ: The increase reflects the product-mix shift, higher sales of lower-margin specialty products, and pricing pressure in pharma.
• Solar power investment doubled: A 16-megawatt captive solar plant was approved with capex of ₹65–70 crores, adding to the 5-megawatt plant already under installation; once both are operational, electricity expenses are expected to be fully nullified.
• Customer inventory levels are unknown: When asked whether customers are holding elevated inventory, management stated they do not have visibility into that.

Guidance & Commitments

Key Metrics